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by administration of corticosteroids prescribed for many nonorthopaedic medical conditions.
We summarised different pathophysiologies of SAON which have adverse effects on multiple
systems such as bone marrow stem cells (BMSCs) pool, bone matrix, cell apoptosis, lipid meta-
bolism, and angiogenesis. Different animal models were introduced to mimic the pathophysi-
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SAON. In the future, genetic analysis might also be helpful to effectively predict the develop-
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with SAON.
Copyrightª 2015, The Authors. Published by Elsevier (Singapore) Pte Ltd. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).of Orthopaedics, Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China.
.com (X.-H. Xie).
.12.002
hors. Published by Elsevier (Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND
licenses/by-nc-nd/4.0/).
Steroid-associated osteonecrosis 59OsteonecrosisOsteonecrosis (ON) is a disabling clinical disease charac-
terised by death of the osteocytes and the bone marrow,
followed by resorption of the necrotic tissues and formation
of new but weaker osseous tissue which leads to a pro-
gressive destruction of bone architecture, subchondral
fracture, and collapse of joints, mostly occurring at the
femoral head, and finally loss of joint function [1e3].
Alexander Munro first reported this medical condition in
1738 and Cruveilhier firstly attributed this disorder to an
aberration of circulation in the femoral head in the mid
1800s [4]. Similar terms to ON include avascular necrosis
(AVN), ischemic necrosis, subchondral AVN, aseptic necrosis
of bone, or osteochondritis dissecans. AVN or ischemic ne-
crosis is used to describe their vascular aetiology, while
aseptic necrosis is used to indicate that the infection does
not play an important role in ON occurrence and its
development. ON occurs mostly in large weight-bearing
joints, such as the hip (Fig. 1) that may subsequently
develop to joint collapse and end up with joint replacement
surgery.
ON can be classified into two types: one is idiopathic
(primary) ON with no apparent aetiologic or risk factor(s);
another is secondary ON in which the aetiology is clearly
identifiable [1], including traumatic and nontraumatic ON.
Steroid-associated ON
Steroid-associated ON (SAON) is a common nontraumatic
ON caused by use of steroids, which are initially prescribed
for many nonorthopaedic medical conditions, including
systemic lupus erythematosus (SLE), organ transplantation,Figure 1 Five stages of osteonecrosis (ON) from X-ray and ma
Research Circulation Osseus (ARCO) staging system on the femora
demonstrable on MRI. At Stage II, there are some radiographic ch
integrity. As the disease progresses, the surface of the femoral h
destroyed (Stage III and Stage IV).asthma, rheumatoid arthritis, and severe acute respiratory
syndrome (SARS). ON in large joints caused by corticoste-
roid administration is usually associated with the worst
prognosis due to the degeneration of the bone around the
prosthesis. Therefore, SAON is the focus of this review
paper where we aim at facilitating multidisciplinary col-
laborations of medical doctors and research scientists
working on SAON.
Aetiology
Of all the nontraumatic factors, corticosteroid usage is the
major associated one [5]. ON development was associated
with dose and duration of administrating corticosteroids
[6]. Usually, the chronic administration of high-dose ste-
roids will result in ON, but it is very difficult to predict
which patient under steroid administration will finally
develop ON. Dynamic magnetic resonance imaging (MRI)
was a promising method for potentially better prediction in
an SAON rabbit model [7] and human trials shall be con-
ducted to confirm the value of SAON development already
in Phase 0. A retrospective study showed that the interval
between steroid administration and the ON onset was from
6 months to > 3 years. The prospective study using MRI to
detect early ON of the femoral head showed that the initial
changes of necrosis were found at about 3 months after
administration of steroids.
Epidemiology
Steroids are now the second most common cause of ON
after trauma and the prevalence of ON varies between 3%
and 38% [3]. Five to twenty-five percent of patients withgnetic resonance imaging (MRI) according to the Association
l head. At Stage I, there are no visible changes on X-ray but
anges in the femoral head, but the joint surface maintains its
ead begins to collapse and finally the integrity of the joint is
60 X.-H. Xie et al.atraumatic ON are a result of steroid administration and 5%
of patients with a history of high-dose corticosteroid
administration developed ON. In Hong Kong and the region,
up to 20% ON incidence was reported following treatment
of SLE patients, patients with organ transplantation, and
SARS patients with steroids. The ON appearances on MRI in
patients under steroid treatment were the same as those
caused by other aetiologies or conditions. It was reported
that at least one ON lesion was found in 31% (138/448) of
SARS patients after steroid therapy from Beijing Jishuitan
Hospital, China [6].
Although ON is seen in any age group, most patients are
young adults, with about 75% between 30 years of age and
60 years of age and with the average age in the late 30s.
The overall male-to-female ratio is about 4:1, while the
prevalence of this ratio is about 7:3 in SLE patients [3].
New cases of ON at the femoral head in the United
States numbered between 10,000 and 20,000 each year and
about 5e10% of them ended up with total hip joint
replacement [1]. In China, there are a total of 4 million
patients with femoral head ON and the number of total
joint replacements in ON patients is increasing.
Histopathology
Histopathologically, the ON lesion is characterised by the
diffuse presence of empty lacunae or pyknotic nuclei of
osteocytes in bone trabeculae, accompanied by surround-
ing necrotic bone marrow [8e10]. Decreased trabecular
width and increased number of apoptotic osteoblasts
and osteocytes were also identified in patients withFigure 2 Pathophysiology of steroid-associated osteonecrosis (SA
by authors of this review paper and others). BMSC Z bone marrowglucocorticoid administration. There were two repair types
in ON lesions in SAON found by others and us. Appositional
bone formation with osteoblast-like cells around the
necrotic lesion is classified as reparative osteogenesis,
whereas granulation tissue creep linked to necrotic bone
resorption is classified as destructive repair [9,11,12]. In
terms of destructive repair, the necrotic bone will subse-
quently induce an inadequate repair process, i.e., the
predominant resorption of necrotic bone exceeds bone
formation that frequently leads to subchondral collapse. In
terms of reconstructive repair in the femoral head, repar-
ative bone formation starts from subchondral fractures
and/or the reactive interface, that finally reduces the size
of the necrotic lesion.
Pathophysiology
The pathophysiology of SAON remains controversial and
different mechanisms including the abnormality of the
bone marrow stem cell (BMSC) pool, hyperlipidemia, fat
emboli, hypercoagulable condition, vascular endothelial
dysfunction, and apoptosis of bone tissues have been pro-
posed extensively. SAON is not caused by only one factor
but multiple factors and these influence each other during
the process of SAON development (Fig. 2), which subse-
quently results in marrow ischaemia and eventually ON.
Abnormality of BMSCs pool
The recent advance in understanding the pathophysiolog-
ical mechanism of the inadequate repair at the early stage
of SAON is on a decreased activity of BMSCs pool [13e15].ON) with different pathways (summarised from published work
stem cell; VEGF Z vascular endothelial growth factor.
Steroid-associated osteonecrosis 61Steroids can induce differentiation of BMSCs into adipo-
cytes linage by upregulating adipocytes transcription factor
gene expression (Peroxisome proliferator-activated recep-
tor gamma adipose-specific 422 and adipsin) and inhibit
their osteogenic differentiation by downregulating osteo-
blast transcription factor gene expression [Cbfa1/Runx2,
type I collagen, bone morphogenetic protein (BMP-2),
osteocalcin, osteopontin, and osteonectin, and osteo-
calcin], thus resulting in increased lipid deposition
including larger fat cells number and its area fraction.
Clinically, Gangji and Hernigou reported decreased number
and osteogenic differentiation ability of BMSCs pool in iliac
or femora in patients with SAON, which resulted in the
inadequate lesion repair at early stage of ON [13e15]. The
authors’ group also demonstrated significantly increased
lipid deposition including larger fat cells number and fat
deposition area at the early stage of SAON in an animal
model [9,11,16,17].
Bone matrix degeneration
Decreased bone formation in SAON was regarded as the
common cause of osteoporosis. Weinstein administered
prednisolone to mice and observed a decrease in bone
density, serum osteocalcin, and cancellous bone area along
with trabecular narrowing, accompanied by diminished
bone formation and turnover. Takano-Murakami et al [18]
also recently found that methylprednisolone (MPSL) so-
dium succinate inhibited bone formation by suppressing
osteoblasts proliferation and bone resorption by suppress-
ing the recruitment of osteoclasts precursors [19]. Thus,
the decreased function of osteoblasts and osteoclasts or
impaired balance between the two cell types by cortico-
steroids would result in bone matrix degeneration, which
explained the delayed bone fracture healing in animals or
patients under steroid administration [12].
Articular cartilage degeneration
The cartilage layer could be found detached from the bone
in severe ON under MRI or arthroscopic evaluation. Gluco-
corticoid receptors were present in cartilage and the ste-
roid was revealed to cause cartilage disruption with
acellular areas [20], which indicate that the steroid might
result in the degeneration of articular cartilage. In most
patients, subchondral collapse changes the articular sur-
face, leading to abnormal mechanics (e.g., local stress
concentration) that is believed to be associated with
development of arthritis to the joint [21]. Our study
revealed that the thickness of the subchondral plate of
SAON emus decreased significantly and the articular carti-
lage showed pathological alteration with significantly
decreased thickness as well as the decreased proteoglycans
content located at the collapsed region [22]. Following
subchondral collapse, the cartilage components might be
exposed to the ongoing repair process. Cartilage constitu-
ents may thus promote the development and continuance
of the disease process in ON and explain the localisation of
ON to subchondral bone [23].
Cell apoptosis
As well as bone matrix degradation, SAON was also charac-
terised by the diffuse presence of empty lacunae or pyknotic
nuclei of osteocytes in bone trabeculae [12,24e26]. If thedeath of the bone subsequently induces an inadequate
repair process, the bone underlying the joint surface will be
weakened. The steroid not only decreases the function of
osteoblasts and osteoclasts, but also induces the apoptosis
of osteoblasts and osteocytes. The steroid-treated mice
exhibited a threefold increase in osteoblast apoptosis in
vertebrae and showed apoptosis in 28% of the osteocytes in
metaphyseal cortical bone. Clinical research showed that
nitric oxide metabolism was altered in bone cells during the
development of ON at the femoral head and was accompa-
nied by widespread apoptosis of osteoblasts and osteocytes,
which suggested that the nitric oxide-mediated apoptosis
was a potential mechanism for SAON [27].
A recent study demonstrated that corticosteroid treat-
ment could induce the development of autophagy of oste-
ocytes, suggesting a new mechanism for the effect of
steroids on osteocytes and giving new insight into mecha-
nisms responsible for bone loss in patients with SAON [26].
Abnormality of lipid metabolism and clotting disorders
Ischaemia is a very important pathomechanism of SAON
(Fig. 2). Abnormality of lipid metabolism and clotting disor-
ders of blood are the major events which lead to ischaemia.
High-dose MPSL could induce multifocal ON in conjunction
with thrombocytopenia, hypofibrinogenemia, and hyper-
lipaemia, which resulted in increased blood glutinousness
followed by decreased blood flow. The altered fat meta-
bolism could increase serum lipid levels (triglyceride and
cholesterol) and a fat embolism resulted in vascular occlu-
sion which accelerated the ischaemia. The intravascular
thrombosis resulting from clotting disorders was also the key
pathogenic pathway to cause ischaemia in SAON found by
others and our own studies [7,10,17,28]. A study from our
group showed that the inhibition of both thrombosis and lipid
deposition could reduce the incidence of SAON [11,16],
which proved that the abnormality of lipid metabolism and
clotting disorders were indeed important mechanism for
SAON. It was found that hypercoagulability of plasma
happened after 24 hours of high-doseMPSL treatment, which
might be the pathogenetic factors contributing to the early
stage of SAON and therefore to be used as an index of early
risk factor to predict later SAON occurrence.
Decreased angiogenesis and elevated vasoconstriction
During the development of SAON, the destructive repair at
necrotic lesions was characterised by predominant resorp-
tion of necrotic bone exceeding bone formation accompa-
nied by decreased angiogenesis. Vascular endothelial
growth factor (VEGF) is an important factor to act on the
endothelial cells and induce neovascularisation during bone
healing. Decreased VEGF expression after treatment with
dexamethasone was both dose- and time-dependent. Clin-
ical and animal experiments showed decreased VEGF
expression at the early stage of SAON and increased VEGF in
the reactive nitric oxide lesion at the late stage [Associa-
tion Research Circulation Osseus (ARCO): stage IV] of the
femoral head [29]. As well as the decreased VEGF expres-
sion at the early stage of ON found by others, we also found
increased VEGF expression 2 weeks after ON induction,
which was maintained at Week 6 during the destructive
repair in SAON rabbits, whereas VEGF expression in recon-
structive repair decreased from Week 2 to Week 6 [9].
62 X.-H. Xie et al.Corticosteroids could also inhibit the capillary growth via
suppressing VEGF and collagen synthesis. It was reported
that glucocorticoids could increase Ca2þ uptake in vascular
smooth muscle cells and downregulate the expression of
endothelial nitric oxide synthase, which leads to strong
vessel contraction.
Oxidation injury
Oxidation injury was another pathogenesis for SAON. It was
reported that oxidative injury in BMSCs was demonstrated
shortly (3 days) after the administration of MPSL in a rabbit
model prior to ON development [30]. The significant
increased rate of ON development by using antioxidant
showed that the oxidation injury was not only involved in the
early stage of SAON [27]. Tissue oxidation was proven to be
able to induce cells apoptosis through oxygen free radicals.
Oxidative stress inhibited osteogenic differentiation of pri-
mary rabbit BMSCs and calvarial osteoblasts by stimulating
extracellular signal-regulated kinases (ERKs) and nuclear
factor-kB [31], implying decreased bone formation in SAON.
Genetic traits
As stated before, not all patients who received steroid
administration would develop SAON, because about
11.2e40% of patients with a history of high-dose corticoste-
roid develop ON [32e34]. This indicated the presence of in-
dividual differences in steroid sensitivity. So, genetic traits
may play an important role on predisposing the development
of SAON. It was reported that inherited thrombophilia and
hypofibrinolysis (high factor VIII, factor V Leiden heterozy-
gosity, and resistance to activated protein C) were risk fac-
tors for SAON. Genetic susceptibility factors in SAON include
single nucleotide polymorphism (SNP) and gene mutation.
Most SNP was related with the angiogenesis, drug delivery,
steroid metabolism, lipid metabolism, and drug resistance,
whichmay influence the development of SAON. It seems that
thegenetic analysis showedapotential relationship between
SAON and SNP, which is suggested to be useful for predictingTable 1 Steroid-associated osteonecrosis and the incidence rat
Animal model
(Ref. no.)
Induced protocol
Agent Dosage Usage Dur
Rabbit [8] MPSL 20 mg/kg i.m. Onc
Rabbit [36] MPSL 20 mg/kg i.m. Onc
Rabbit [37] LPS 100 mg/kg/d i.v. 2 d
MPSL 100 mg/kg/d i.m. 3 d
Rabbit [7,10,11] LPS 10 mg/kg i.v. Onc
MPSL 20 mg/kg/d i.m. 3 d
Rat [38] Human serum 10 mL/kg/wk i.p. 2 w
MPSL 40 mg/kg/d i.m. 3 d
Mouse [39] Dexamethasone 4 mg/L Drinking
water
12
Pig [41] MPSL(two steps) 30 mg/kg i.v. Init
5.4 mg/kg/h 23
Chicken
[42]
MPSL 3 mg/kg/wk i.m. 12
i.m. Z intramuscular; i.p. Z intraperitoneal; i.v. Z intrav
MPSL Z methylprednisolone acetate.the development of ON and of benefit to the clinician in
preventing ON as early as possible.SAON animal models
To examine the mechanism or to identify the prevention
and treatment efficiency of the biomaterial or pharmaco-
logical therapy strategies for SAON, different animal
models (Table 1) were built up, including rabbit
[8,10,11,35e37], rat [38], mouse [39,40], pig [41], bipedal
chicken [42], and emu [22]. Among all experimental
models, quadrupedal rabbits are commonly used for
establishing SAON, which was proven to be a good animal
model for developing high ON incidence in our recent work
[7,10,11,43,44] and also by others [8,35,36], yet without
being able to develop to joint collapse, mainly explained by
lower mechanical loading onto the weight-bearing joints.
To induce SAON in rabbits, the administration of single
MPSL [37] was proven to be an efficient method, but the
incidence of ON was about 33.3e43%. Two injections of
high-dose lipopolysaccharide (LPS) combined with a sub-
sequent three injections of high-dose MPSL (H-LPS  2 þ H-
MPSL  3) could improve the incidence of ON but result in
high mortality [37]. In our group, we have developed a
protocol by modifying the reported protocol with a single
low-dose LPS, followed by three times injections of MPS
which had a higher incidence of ON of up to 93%, with lower
or no mortality [7,10,11,43,44]. We also established a
bipedal emu model for testing and supporting Chinese
herbal Epimedium in prevention of SAON with functions in
bone formation stimulation and antiadipogenesis etc. [22].
Although a high incidence of SAON was found in different
animal models, we noted that the incidence rate in humans
was not so high [45], which indicated a difference between
animals and human. It is benefit for us to test the preven-
tion and treatment efficacy in animals with a high incidence
of SAON.e of osteonecrosis in animal models.
IR Time Location Mortality
ation
e 43% 4 wk Femora,
humerus
d
e 72.7% 2 wk Femora d
85.7% 4 wk Femora,
humerus
20%
e 92.86e93.75% 2e6 wk Femora 0
k 90% 2 wk Femora d
wk 40e45% 12 wk Distal femur 17%
ial bolus Reduced blood
fiow
24 h Femora d
h
wk 56% 6 wk Femoral head d
enous; IR Z incidence rate; LPS Z lipopolysaccharide;
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It is very difficult to predict which patients receiving steroids
will develop ON, although prevention of SAON is essential,
e.g., already at the time of steroids treatment [23].
Controlled clinical trials are lacking to show the efficiency of
prevention of SAON occurrence. Most experiments on pre-
vention of SAON were performed using laboratory animals
(Table 2). It was reported from others and our group that the
Chinese herb such as an Epimedium-derived phytoestrogenic
compound or its metabolic products and Liuwei Dihuang pills
[11,16,24,25,46], genistein aglycone [47], a lipid-lowering
agent (lovastatin or pitavastatin) and/or an anticoagulant
(warfarin or enoxaparin) [48], antioxidative substances
(vitamin E) [49], lipoic acid [50], nitrate patch [51], hepatic
CYP3A inducer [52], electromagnetic fields [53], or bone
marrow cells [36] were able to exert partly beneficial effects
on prevention of SAON in differentmodels attributed to their
osteogenic and anti-adipogenic effects, as well as inhibition
of both thrombosis and lipid deposition in a dose-dependent
manner.
Chinese herbs
A lower incidence of SAON happened in Hong Kong and
Guang Zhou in China during explosion of severe acute res-
piratory syndrome (SARS) but was higher in Beijing e
partially explained by use of the antiinflammatory herbs, but
no clinical trials were performed, so our group established
both quadrupedal and bipedal models for testing and sup-
porting herbal Epimedium in the prevention of SAON, withTable 2 Incidence rate (IR) of steroid-associated osteonecrosis
Preventive agents (Ref. no.) Usage
Flavonoids derived from
Epimedium [16,24,25]
Low (10 mg/kg/d)
Middle (20 mg/kg/d)
High (40 mg/kg/d)
per os, 2 wk
Icaritin [11] Low (5 mg/kg/d)
High (10 mg/kg/d)
per os, 2 wk
Genistein aglycone [47] 5 mg/kg/d, i.p., 60 days
Liuwei Dihuang pills [46] 2 g/kg/d, per os, 8 wk
Statins drugs [45] At least 1 y duration
Lovastatin [48] 5 mg/kg/d, per os, 14 wk
Enoxaparin þ lovastatin [48] Enoxaparin: 1 mg/kg/d, s.c., 4 wk
lovastatin: 5 mg/kg/d, per os, 14
Vitamin E [49] 50 mg/kg/d, i.v., 2 wk
Lipoic acid [50] 36 mg/kg/d, i.p., 4 wk
Nitrate patch [51] 0.675 mg/d, per os, 4 wk
Hepatic CYP3A inducer [52] 25 mg/kg/d, i.m., 6 wk
Electromagnetic fields [53] 15 Hz, 10 h/d, 5 wk
Autologous bone marrow
cells [36]
1  107cells, intra-bone marrow
injection, once
i.m. Z intramuscular; i.p. Z intraperitoneal; i.v. Z intravenous; s.cfunctions in bone formation stimulation, anti-adipogenesis
etc. [7,10,11,16,24,25]. Liuwei Dihuang pills and Huogu I
formula can prevent SAON by improving lipid metabolism,
relieving bone lesions, and protecting against cell death
[46,54]. Genistein aglycone, an isoflavone acting on de novo
protein synthesis and on amplification of the interaction
between the oestrogen receptor complex and nuclear DNA in
osteoblasts, could prevent complications of ON with long-
term glucocorticoid treatment due to its action on trabec-
ular bone by amechanism involving estrogen receptor (ER)-b
upregulation during the bone mineralisation phase [47].Lipid-lowering agent
It was reported that statins usage can partly lower the risk
of ON. A retrospective report from Pritchett [59] showed
that the ON incidence was only 1% in 284 patients who had
received high-dose corticosteroids while under concurrent
statins administration, which was significantly lower than
the historical value of 3e20% without adjunct therapy [55].
Ajmal et al [45] analysed the renal transplant database to
prove that statins usage could reduce the incidence of
SAON and identified 2881 renal transplantation patients
who met the entry criteria of ON. Among patients who used
statins, 4.4% developed ON, versus 7% in patients who were
not on statins. The prevention of SAON in animal experi-
ments showed that statins could prevent SAON develop-
ment due to their inhibition of adipogenesis and lipid
deposition, reduction of blood viscosity by suppressing
PPAR(sup) expression and activating the Wnt signalling
pathway [42,56,57]. Enoxaparin, one of the anticoagulants,in different models with different preventive agents.
Model IR without
prevention
IR with prevention
Rabbit 93% Low (56%)
Middle (13%)
High (6%)
Rabbit 93.75% Low (56.25%)
High (6.25%)
Rat Histological
score: 3
Histological score: 0.5
Mice Rate of empty
lacunae: 28%
Rate of empty lacunae: 8%
Human 7% 4.4%
Rabbit 68% 35%
;
wk
Rabbit 68% 15%
Rabbit 93% 0%
Rabbit 73.1% 20.8%
Rabbit Empty lacunae:
4/mm2
Empty lacunae: 1.5/mm2
Rabbit 83% 33%
Rabbit 65% 37.5%
Rabbit 72.7% 0%
. Z subcutaneous.
64 X.-H. Xie et al.has less ability to inactivate thrombin and can reduce the
incidence of steroid-induced ON in rabbits when combined
with lovastatin [48].
Antioxidative substances
Increased oxidative stress is considered as a crucial cause of
SAON. Antioxidative substances such as vitamin E, lipoic
acid, and fullerol may alleviate oxidative injury following
corticosteroid administration, and thus prevent ON.
Vitamin E is a fat-soluble substance in the body that
significantly inhibited steroid-induced oxidative stress [49].
Lipoic acid can prevent the development of SAON by
inhibiting oxidative stress and amendment of vascular
endothelial dysfunction [50]. Fullerol inhibits adipogenesis
and simultaneously enhances osteogenesis by marrow
mesenchymal stem cells, possibly through elimination of
cellular reactive oxygen species [58].
Nitrate patch
A nitrate patch, an agent which generates vasodilation in
bone, had preventive effects against SAON. The substance
released from the nitrate patch might replace the deficient
NO and counteract the vasoconstriction [51].
Hepatic cytochrome P4503A (CYP3A) inducer
Hepatic cytochrome P4503A (CYP3A) is a predominant
enzyme responsible for metabolising corticosteroids, and
hepatic CYP3A levels are significantly lower in patients with
SAON. Hepatic CYP3A activity induced by phenobarbital
was inversely correlated with the incidence of ON and
extent of the necrotic area caused by the same dose of
corticosteroids, suggesting prevention of SAON by reducing
steroid dose in poor corticosteroid metabolisers [52].
Electromagnetic fields
Electromagnetic stimulation could prevent SAON in rabbit
and rat models, and the underlying mechanisms involved
decreased serum lipid levels and increased expression of
transforming growth factor b1 (TGF-b1) [53]. The authors
also found that this treatment can help prevent ON, but if it
occurs, the treatment does not reduce its severity.
Injection of autologous bone marrow cells
Injection of autologous bone marrow cells directly into the
femurs could prevent SAON in rabbits treated with high-
dose steroid because of their regulation of fibrinogenolysis
and coagulation in the peripheral blood [36].
Antiapoptotic agents
Prevention of glucocorticoid-induced apoptosis in osteo-
cytes and osteoblasts might be a potential method to pre-
vent the development of ON. Calcium-binding protein
calbindin-D28k, and granulocyte colony stimulating factor
and stem cell factor have been reported to preventglucocorticoid-induced bone cell death through inhibition
of glucocorticoid-induced caspase 3 activation, as well as
ERKs activation [59,60]. Bisphosphonates and calcitonin
promoted a rapid increase in the phosphorylated fraction of
ERKs and inhibited the apoptosis of osteocytes and osteo-
blasts following prednisolone administration to mice.
Recently, the skeletal muscle secreted factors were found
to prevent glucocorticoid-induced osteocyte apoptosis
through activation of b-catenin.
The prevention effects of SAON by different agents are
summarised in Table 2. Each agent reported in the pub-
lished studies showed positive effects on SAON prevention,
but most of them were generated from animal experi-
ments. Available human studies demonstrated that statins
were able to decrease the incidence of SAON as well [45],
but the prevention efficiency was lower than that gener-
ated from animal models. This might be explained by the
fact that the SAON was caused not by a single but by
multiple pathophysiologies (Fig. 2) and should be pre-
vented by several measures combined together. More
clinical tests and trials are desirable in future, especially
with those agents with known mechanisms discussed
above.Treatment of SAON
Treatment of SAON is a big challenge, as sufficiently large
prospective controlled studies are lacking. According to the
different stages of ON (ARCO classification), there are
several treatments available for SAON, including nonoper-
ative and operative therapy (Table 3).
Nonoperative treatment
Nonsurgical treatments of ON are limited and are commonly
indicated for patients at the early stage of ON with local-
ised necrotic lesions. The objects of such intervention
usually focus on pain relief, prevention of ON progression,
and improvement of the joint function. According to the
different pathophysiologies of SAON, numerous medical and
biophysical treatments have been tested and have
demonstrated treatment efficacy, especially for patients in
early ON stages, including biological and pharmacological
treatments such as statins [45,55], bisphosphonates [61],
low molecular weight heparin [62], stanozolol, iloprost,
hyperbaric oxygen, herbal (puerarin and Epimedium)
[11,16] or nonpharmacological treatments including extra-
corporeal shock wave therapy [63,64] and electromagnetic
therapy [65,66].
Operative treatment
Operative treatment alternatives for femoral head ON
mainly include osteotomy, core decompression seques-
trectomy, bone and/or cells grafting, and total hip arthro-
plasty. The age and general health of patients, ON stage
particularly with collapse of the femoral head and/or
acetabular involvement, and size and location of lesions are
the common determining factors for considering operation
options.
Table 3 Approaches for diagnosis and stage-based interventions according to Association Research Circulation Osseus (ARCO)
staging system.
Stages Diagnosis Treatment
Stage 0 Bone biopsy, bone scan, MRI Prevention:
Pharmacotherapy
Physical therapy
Stage I Bone scan, MRI 1. Nonoperative treatment:
Pharmacotherapy
Physical therapy
2. Operative treatment:
Core decompression
Core decompression with bone grafting
Core decompression with bone marrow
Core decompression with cells
Core decompression with growth factors
Tissue-engineered approach
Stage II Radiographs or CT, bone scan, MRI Operative treatment:
Core decompression
Core decompression with bone grafting
Core decompression with bone marrow
Core decompression with cells
Core decompression with growth factors
Tissue-engineered approach
Osteotomy
Stage III Radiographs Operative treatment:
Core decompression with bone grafting
Core decompression with bone marrow
Core decompression with cells
Core decompression with growth factors
Tissue-engineered approach
Osteotomy
Arthrodesis
Total hip arthroplasty
Stage IV Radiographs Operative treatment:
Arthrodesis
Total hip arthroplasty
CT Z computed tomography; MRI Z magnetic resonance imaging.
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Intertrochanteric rotational osteotomy or flexion osteot-
omy is joint-preserving therapy for SAON by which the
osteonecrotic lesion is rotated away from the weight-
bearing area. However, the specific complications are
bony nonunion and pseudarthrosis.
Core decompression
Core decompression through creation of a surgical drilled
bone tunnel is one of the least invasive surgical procedures
in early ON stages when the ON lesion is still small (Fig. 3).
Core decompression is usually performed in Ficat Stage II or
earlier stages to prevent the subchondral collapse in SAON.
Biologically, it helps to reduce intraosseous pressure and
provide a conduit for angiogenesis to revascularise sub-
chondral bone. However, concerns still do exist, including
those related to incomplete reconstructive repair and its
potential to weaken the trabecular bone within and next to
the necrotic region when the necrotic lesion was relatively
large [1,67,68]. However, once the femoral head develops a
subchondral fracture, the efficacy of the core decompres-
sion will drop significantly.Bone grafting
In order to reinforce the surgically-induced bone defect
resulting from core decompression sequestrectomy and
delay the need for arthroplasty, several types of bone
grafts have been used to provide mechanical support for
the affected joint in Ficat Stage III or in even earlier stages
(Fig. 4). These include autogenous or allogenous cortical
bone grafts of ilium, fibula, or tibia alone, or alternatively,
these procedures may be combined with core decompres-
sion [1,3]. A vascularised bone graft was used that showed
some superior results as compared with most other pro-
cedures designed to preserve the femoral head collapse
[69,70]. The autologous bone graft is used as a good sub-
stitute of the necrotic site, but limitations include insuffi-
cient supply and variation in the osteogenic potential of the
graft material. The harvesting of host bone often results in
donor site morbidity. Fresh osteochondral allografting is a
reasonable salvage option for ON of the femoral condyles,
thus total knee arthroplasty (TKA) was avoided in 27 of the
28 of knees at last follow-up [71]. Tantalum rod implanta-
tion is a safe “buy-time” technique, especially when other
joint salvage procedures are not an option [72]. Tantalum
Figure 5 Femoral head with osteonecrosis (ON) treated with
tantalum rod implantation (arrow).
Figure 3 Core decompression procedure (arrow) of femoral
head with steroid-associated osteonecrosis (SAON).
66 X.-H. Xie et al.rod implantation (Fig. 5) combined with bone grafting is an
effective joint-preserving method for the treatment of
intermediate-stage ON of the femoral head [73,74].
Recently, the PLGA/tricalcium phosphate (TCP)/icaritin
scaffold could be used to treat bone defects in rabbits with
SAON [75].
Bone marrow or BMSCs transplantation
Due to the decreased activity of MSCs pool within or around
ON lesions in SAON, additional MSCs or bone marrowFigure 4 Femoral head with osteonecrosis (ON) treated with
allogenous bone graft (arrow).grafting are promising treatment options for SAON attrib-
uted to their differentiation properties, easy accessibility,
and proliferative capacity [76e78]. Clinically, good results
were generously reported from treatment of SAON using
autologous bone marrow grafts combined with core
decompression and those who had the greater number of
progenitor cells transplanted in ON lesions had better out-
comes [13,14,79]. Most of the bone marrow was collected
from the iliac crest, but it was reported that the bone
marrow near the site of ON could also be used [80]. Their
surgical procedure was less invasive, but it might not be
effective for large ON lesions because of larger marrow
spacing created after core decompression sequestrectomy.
In addition, the animal studies also showed that bone
marrow mononuclear cells were beneficial for vascularisa-
tion and bone regeneration in SAON [35,78]. Trans-
plantation of autologous endothelial progenitor cells was
also beneficial for SAON at the femoral head in rabbits [81].
Although the supplement of enough cells could enhance the
repair of ON lesions, we also realise that the implanted
cells might lose their ability to repair, as it was found that
the pluripotential marrow cells produced adipocytes when
they were transplanted into steroid-treated mice [82].
Growth factors
Growth factors such as BMPs and VEGF are osteogenic or
angiogenic to promote the bone or vessel formation. BMPs
are osteoinductive growth factors that induce osteogenic
cell differentiation in vitro and osteogenesis in bone heal-
ing in vivo. The growth factors can be used for ON treat-
ment directly or combined with bone graft after core
decompression [83]. The growth factor genes could also be
transfected into BMSCs and were capable of treating the ON
in its early stage(s), e.g., demonstrated at the femoral
head in rabbit or goat models and the promoted osteo-
genesis and angiogenesis were observed [84].
Steroid-associated osteonecrosis 67Tissue-engineered approach
Although core decompression with supplementation of
BMSCs could be used to treat ON, it might not be effective
for large ON lesions or post collapse cases. Due to the
apoptosis of osteocytes and degeneration of trabecular
bone matrix in the femora, the bone harvested showed
decreased viability in SAON. Kawate used tissue-engineered
approach for treating SAON in the femoral head, where
cultured BMSCs/b-TCP composite granules were implanted
into the cavity that remained after curettage of necrotic
bone, together with a subsequent free vascularised tibia
grafting [85]. BMSCs/biphasic calcium phosphate ceramic
scaffolds and porous b-TCP loaded with BMP-2-gene-trans-
duced BMSCs performed in animal models also provided
effective treatment results [84,86].
Total hip arthroplasty
Total hip arthroplasty (Fig. 6) is usually used primarily for
ON Stages III and IV, but occasionally also used for Stages I
and II. The prognosis of joint replacement is poor in pa-
tients with idiopathic or traumatic ON, but still better as
compared with SAON patients. The aetiology of ON did not
normally affect the final outcome, but less favourable long-
term results were found in SAON patients. Patients with
femoral head ON are generally young and total hip arthro-
plasty is often an unfavourable choice. Joint preservation is
too difficult due to large pre collapse lesions and post
collapse disease, so surgical alternatives for these patients
may also include limited femoral resurfacing and bipolar
hemiarthroplasty. However, the most useful and common
treatment is total hip arthroplasty.
Summary and further translational research
In conclusion, ON is a challenging orthopaedic condition
which resulted from unwanted adverse effects ofFigure 6 Femoral head with osteonecrosis (ON) treated with
total hip arthroplasty.corticosteroids administration. Normally, no single factor is
involved in the pathophysiology of SAON initiation and its
development. Evaluation of approaches developed for
prevention and treatment of ON in both animal and human
studies indicated that a certain pathophysiology resulted in
ON, including abnormality of BMSCs pool, bone matrix and
cartilage degeneration cell apoptosis, abnormality of lipid
metabolism and clotting disorders, decreased angiogenesis
and elevated vasoconstriction, and oxidation injury. Or-
thopaedic surgery is important for the treatment of SAON,
yet its prognosis is rather poor. This implies the importance
of prevention in two aspects, including: (1) to prevent the
happening of SAON after the administration of steroid; and
(2) to prevent the development of SAON from early stage to
late stage.
Based on the possible pathophysiology and the effective
prevention or therapy performed in animals and humans
with steroid administration, much more bench to clinic
translational work shall be done in the future to promote
efficiency of early prevention, diagnosis, and treatment of
SAON. Good prevention requires good predictive diagnosis.
Gene analysis or hypercoagulability of plasma might be
earlier methods to predict ON development, although dy-
namic perfusion MRI is another advanced and promising
bioimaging approach. Chinese herb and statins treatment
produced significantly lower incidences of SAON both in
humans and animal models, implying that they might be
promising alternatives for prevention and eventually
treatment of SAON. The apoptosis of osteoblasts, osteo-
clasts, and osteocytes suggested a new mechanism for the
effect of steroids, giving a new insight into mechanisms
responsible for bone loss in patients with SAON. Core
decompression combined with bone grafting, bone marrow
or cells transplantation, and growth factors is the best
documented therapy for early SAON stage(s). The newly
tested osteopromotive porous composite scaffolds were
also promising for enhancing repair of ON lesions after core
decompression [87,88]. Gene therapy was proven to be
effective in animal models, but its safety and ethical issues
are still controversial. Despite all treatments, joint
replacement is still advocated for patients at the late ON
stage(s). How to improve postoperative prognosis after
joint replacement therapy remains a challenging topic for
not only orthopaedic surgeons, but also biomedical engi-
neers and biomaterial scientists. We hope that with all
collective efforts, more scientifically confirmed approaches
will be available for clinical applications and will benefit
patients suffering from ON, especially SAON.Conflicts of interest
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